Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALNY | Common Stock | Award | $0 | +5.08K | +36.56% | $0.00 | 19K | Aug 3, 2022 | Direct | F1 |
transaction | ALNY | Common Stock | Award | $0 | +4.15K | +21.88% | $0.00 | 23.1K | Aug 3, 2022 | Direct | F2 |
transaction | ALNY | Common Stock | Award | $0 | +3.86K | +16.68% | $0.00 | 27K | Aug 3, 2022 | Direct | F3 |
transaction | ALNY | Common Stock | Tax liability | -$1.03M | -5.43K | -20.12% | $189.76 | 21.6K | Aug 4, 2022 | Direct | F4 |
transaction | ALNY | Common Stock | Tax liability | -$40.9K | -195 | -0.9% | $209.83 | 21.4K | Aug 4, 2022 | Direct | F4 |
transaction | ALNY | Common Stock | Tax liability | -$40.7K | -194 | -0.91% | $209.85 | 21.2K | Aug 4, 2022 | Direct | F4 |
transaction | ALNY | Common Stock | Tax liability | -$37.8K | -180 | -0.85% | $210.25 | 21K | Aug 4, 2022 | Direct | F4 |
holding | ALNY | Common Stock | 407 | Aug 3, 2022 | by Managed Account | F5 |
Id | Content |
---|---|
F1 | On February 26, 2020, the reporting person was granted performance-based stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and the second one-third of the PSU award vested as of August 3, 2022. |
F2 | On October 7, 2020, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022. |
F3 | On February 24, 2021, the reporting person was granted performance-based stock units (PSU) in connection with the 2020 year-end compensation review. One quarter of the PSU award vests upon the achievement of each of four specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and the first quarter of the PSU award vested as of August 3, 2022. |
F4 | Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. |
F5 | Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |